CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

A Novel Circulating MicroRNA for the Detection of Acute Myocarditis Prognostic Value of SYNTAX Score in Patients With Infarct-Related Cardiogenic Shock: Insights From the CULPRIT-SHOCK Trial The Prognostic Significance of Periprocedural Infarction in the Era of Potent Antithrombotic Therapy: The PRAGUE-18 Substudy Deficiency of GATA3-Positive Macrophages Improves Cardiac Function Following Myocardial Infarction or Pressure Overload Hypertrophy Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES Phosphoproteomic Analysis of Neonatal Regenerative Myocardium Revealed Important Roles of CHK1 via Activating mTORC1/P70S6K Pathway Red Cell Distribution Width in Patients with Diabetes and Myocardial Infarction: an analysis from the EXAMINE trial Predicting Major Adverse Events in Patients With Acute Myocardial Infarction

Original Research2021 Mar 9.

JOURNAL:Diabetes Obes Metab. Article Link

Red Cell Distribution Width in Patients with Diabetes and Myocardial Infarction: an analysis from the EXAMINE trial

JP Ferreira, Z Lamiral, G Bakris et al. Keywords: alogliptin; outcomes; red cell distribution width; T2DM

ABSTRACT

BACKGROUND - Red blood cell distribution width (RDW) is a measure of size variability in the red blood cell population (anisocytosis). Increased RDW may arise from any condition that affects erythropoiesis or the survival of erythrocytes. RDW has been associated with poor prognosis in patients with type 2 diabetes (T2D). Whether RDW is a risk marker for adverse cardiovascular outcomes or also a marker of noncardiovascular health concerns is of clinical importance.

 

AIMS - To determine the clinical correlates of increased RDW, its potential mechanistic association with multiple circulating biomarkers, and its prognostic value, in patients with (T2D) who had a recent acute coronary syndrome.

 

METHODS - We used timeupdated Cox models applied to patients enrolled in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

 

RESULTS - A total of 5380 patients were included, the median age was 61 years and 32% were women. Patients with higher RDW were older, more frequently women, with longer duration of diabetes duration, and increased comorbidities. An RDW >16.1% (both baseline and timeupdated) was independently associated with the study primary composite outcome of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death (timeupdated adjusted HR =1.36, 95%CI =1.161.61, p < 0.001), allcause death (timeupdated adjusted HR =2.01, 95%CI =1.602.53, p < 0.001), as well as mortality from nonCV causes (timeupdated adjusted HR =2.67, 95%CI =1.724.15, p < 0.001). RDW had a weaktomoderate correlation with hemoglobin and circulating markers that reflected inflammation, apoptosis, fibrosis and congestion. Alogliptin did not alter RDW values.

 

CONCLUSIONS - RDW is a marker of disease severity associated with a multitude of poor outcomes, including both cardiovascular and noncardiovascular death. RDW correlated modestly with inflammatory, proapoptotic, profibrotic, and congestion markers, and its levels were not affected by alogliptin during the course of the trial.

 

This article is protected by copyright. All rights reserved.